Functional Dyspepsia and Gastroesophageal Reflux Disease: From Pathogenesis to Current Treatment Strategies
https://doi.org/10.22416/1382-4376-2024-34-5-83-92
Abstract
Aim: to present a modern view on the combination of functional dyspepsia (FD) and gastroesophageal reflux disease (GERD) and to evaluate the effectiveness of acotiamide in patients with FD and GERD.
Key points. The high frequency of the combination of FD and GERD is caused by common pathogenetic mechanisms and presents an urgent problem in clinical practice. The concurrent occurrence of these diseases alters the clinical picture, complicates differential diagnostics, and leads to inadequate prescription of drugs. Medical treatment for patients with FD and GERD includes the use of proton pump inhibitors (PPIs) and prokinetics. Currently, acotiamide is recognized as an effective drug that affects the motility of the upper gastrointestinal tract. Acotiamide is an antagonist of muscarinic M1 and M2 receptors and a reversible inhibitor of acetylcholinesterase. The clinical efficacy of this drug has been demonstrated not only in patients with FD but also in those with a combination of FD and GERD.
Conclusion. Administration of acotiamide is pathogenetically justified in patients with the combination of GERD and FD.
Supporting agencies: this publication is supported by Dr. Reddy’s Laboratories Ltd.
About the Authors
A. S. Trukhmanov
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Alexander S. Trukhmanov — Dr. Sci. (Med.), Professor at the Department of Internal Diseases Propaedeutics, Gastroenterology and Hepatology, N.V. Sklifosovsky Institute of Clinical Medicine.
119435, Moscow, Pogodinskaya str., 1, build. 1
D. E. Rumyantseva
I.M. Sechenov First Moscow State Medical University (Sechenov University)
Russian Federation
Russian Federation
Diana E. Rumyantseva — Cand. Sci. (Med.), Doctor of the Gastroenterology Department, V.Kh. Vasilenko Clinic of Internal Diseases Propaedeutics, Gastroenterology and Hepatology.
119435, Moscow, Pogodinskaya str., 1, build. 1
References
1. Ford A.C., Marwaha A., Sood R., Moayyedi P. Glob al prevalence of, and risk factors for, uninvestigated dyspepsia: A meta-analysis. Gut. 2015;64(7):1049–57. DOI: 10.1136/gutjnl-2014-307843
2. Lee K., Kwon C.I., Yeniova A.Ö., Koyanagi A., Jacob L., Smith L., et al. Global prevalence of functional dyspepsia according to Rome criteria, 1990–2020: A systematic review and meta-analysis. Sci Rep. 2024;14(1):4172. DOI: 10.1038/s41598-024-54716-3
3. Ivashkin V.T., Maev I.V., Trukhmanov A.S., Lapina T.L., Storonova O.A., Zayratyants O.V., et al. Recommendations of the Russian Gastroenterological Association in diagnosis and treatment of gastroesophageal reflux disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(4):70–97. (In Russ.). DOI: 10.22416/1382-4376-2020-30-4-70-97
4. Eusebi L.H., Ratnakumaran R., Yuan Y., Solaymani-Dodaran M., Bazzoli F., Ford A.C. Global preva lence of, and risk factors for, gastro-oesophageal reflux symptoms: A meta-analysis. Gut. 2018;67(3):430–40. DOI: 10.1136/gutjnl-2016-313589
5. Stanghellini V., Chan F.K.L., Hasler W.L., Malagelada J.R., Suzuki H., Tack J., et al. Gastroduode nal disorders. Gastroenterology. 2016;150(6):1380–92. DOI: 10.1053/j.gastro.2016.02.011
6. Kaji M., Fujiwara Y., Shiba M., Kohata Y., Yamagami H., Tanigawa T., et al. Prevalence of overlaps between GERD, FD and IBS and impact on health-related quality of life. J Gastroenterol Hepatol. 2010;25(6):1151–6. DOI: 10.1111/j.1440-1746.2010.06249.x
7. Haque M., Wyeth J.W., Stace N.H., Talley N.J., Green R. Prevalence, severity and associated features of gastro-oesophageal reflux and dyspepsia: A population-based study. N Z Med J. 2000;113(1110):178–81.
8. Choung R.S., Locke G.R. 3rd, Schleck C.D., Zinsmeister A.R., Talley N.J. Overlap of dyspepsia and gastroesophageal reflux in the general population: One disease or distinct entities? Neurogastroenterol Mo til. 2012;24(3):229–34, e106. DOI: 10.1111/j.13652982.2011.01845.x
9. Guillemot F., Ducrotté P., Bueno L. Prevalence of functional gastrointestinal disorders in a population of subjects consulting for gastroesophageal reflux disease in general practice. Gastroenterol Clin Biol. 2005;29(3):243–6. DOI: 10.1016/s0399-8320(05)80756-0
10. Lee S.W., Lee T.Y., Lien H.C., Yeh H.Z., Chang C.S., Ko C.W. The risk factors and quality of life in patients with overlapping functional dyspepsia or peptic ulcer disease with gastroesophageal reflux disease. Gut Liver. 2014;8(2):160–4. DOI: 10.5009/gnl.2014.8.2.160
11. Monnikes H., Schwan T., van Rensburg C., Straszak A., Theek C., Sander P., et al. Randomized clinical trial: Sustained response to PPI treatment of symptoms resembling functional dyspepsia and IBS in patients suffering from an overlap with erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2012;35(11):1279–89. DOI: 10.1111/j.1365-2036.2012.05085.x
12. Noh Y.W., Jung H.K., Kim S.E., Jung S.A. Overlap of erosive and non-erosive reflux diseases with functional gastrointestinal disorders according to Rome III criteria. J Neurogastroenterol Motil. 2010;16(2):148–56. DOI: 10.5056/jnm.2010.16.2.148
13. Sheptulin A.A., Kurbatova A.A., Baranov S.A. Modern options of prokinetics in gastroesophageal reflux disease treatment. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(1):71–7. (In Russ.). DOI: 10.22416/1382-4376-2018-28-1-71-77
14. Trukhmanov A.S., Ivashkina N.Yu. The clinical significance of disorders of the motor function of the esophagus, stomach and duodenum. Terapevticheskii arkhiv. 2019;91(8):127–34. (In Russ.). DOI: 10.26442/00403660.2019.08.000390
15. Wauters L., Dickman R., Drug V., Mulak A., Ser ra J., Enck P., et al. United European Gastroenterology (UEG) and European Society for Neurogastroenterology and Motility (ESNM) consensus on functional dyspepsia. United European Gastroenterol J. 2021;9(3):307–31. DOI: 10.1002/ueg2.12061
16. Ivashkin V.T., Mayev I.V., Sheptulin A.A., Lapina T.L., Trukhmanov A.S., Kartavenko I.M., et al. Diagnosis and treatment of the functional dyspepsia: Clinical guidelines of the Russian Gastroenterological Association. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2017;27(1):50–61. (In Russ.). DOI: 10.22416/1382-4376-2017-27-1-50-61
17. Tack J., Piessevaux H., Coulie B., Caenepeel P., Janssens J. Role of impaired gastric accommodation to a meal in functional dyspepsia. Gastroenterology. 1998;115(6):1346–52. DOI: 10.1016/s0016-5085(98)70012-5
18. Camilleri M., Hasler W.L., Parkman H.P., Quig ley E.M., Soffer E. Measurement of gastrointesti nal motility in the GI laboratory. Gastroenterology. 1998;115(3):747–62. DOI: 10.1016/s0016-5085(98)70155-6
19. Lin Z., Eaker E.Y., Sarosiek I., McCallum R.W. Gastric myoelectrical activity and gastric emptying in patients with functional dyspepsia. Am J Gastroenterol. 1999;94(9):2384–9. DOI: 10.1111/j.15720241.1999.01362.x
20. Storonova O.A., Trukhmanov A.S., Ivashkin V.T. High resolution manometry in clinical practice: Analysis of the motor function of the esophagus in accordance with the Chicago classification. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2018;28(2):11–23. (In Russ.). DOI: 10.22416/13824376-2018-28-2-11-23
21. Ivashkin V.T., Mayev I.V., Trukhmanov A.S., Storonova O.A., Abdulkhakov S.R., Andreev D.N., et al. Recommendations of the Russian Gastroenterological Association on clinical use of high-resolution manometry in diagnosis of esophageal disorders. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2020;30(3):61–88. (In Russ.). DOI: 10.22416/1382-4376-2020-30-3-61-88
22. Pauwels A., Altan E., Tack J. The gastric accommodation response to meal intake determines the occurrence of transient lower esophageal sphincter relaxations and reflux events in patients with gastro-esophageal reflux disease. Neurogastroenterol Motil. 2014;26(4):581–8. DOI: 10.1111/nmo.12305
23. Herregods T.V., Bredenoord A.J., Smout A.J. Pathophysiology of gastroesophageal reflux disease: New understanding in a new era. Neurogastroenterol Motil. 2015;27(9):1202–13. DOI: 10.1111/nmo.12611
24. Gonlachanvit S., Maurer A.H., Fisher R.S., Park man H.P. Regional gastric emptying abnormalities in functional dyspepsia and gastro-oesophageal reflux disease. Neurogastroenterol Motil. 2006;18(10):894–904. DOI: 10.1111/j.1365-2982.2006.00811.x
25. Tack J., Caenepeel P., Fischler B., Piessevaux H., Janssens J. Symptoms associated with hypersensitivity to gastric distention in functional dyspepsia. Gastroenterology. 2001;121(3):526–35. DOI: 10.1053/gast.2001.27180
26. Cicala M., Emerenziani S., Caviglia R., Guari no M.P., Vavassori P., Ribolsi M., et al. Intra-oesophageal distribution and perception of acid reflux in patients with non-erosive gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2003;18(6):605–13. DOI: 10.1046/j.1365-2036.2003.01702.x
27. Emerenziani S., Sifrim D., Habib F.I., Ribolsi M., Gua rino M.P., Rizzi M., et al. Presence of gas in the refluxate enhances reflux perception in non-erosive patients with physiological acid exposure of the oesophagus. Gut. 2008;57(4):443–7. DOI: 10.1136/gut.2007.130104
28. Orlando L.A., Orlando R.C. Dilated intercellular spaces as a marker of GERD. Curr Gastroenterol Rep. 2009;11(3):190–4. DOI: 10.1007/s11894-009-0030-6
29. Walker M.M., Talley N.J. The role of duodenal inflammation in functional dyspepsia. J Clin Gastroenterol. 2017;51(1):12–8. DOI: 10.1097/MCG.0000000000000740
30. Cirillo C., Bessissow T., Desmet A.S., Vanheel H., Tack J., Vanden Berghe P. Evidence for neuronal and structural changes in submucous ganglia of patients with functional dyspepsia. Am J Gastroenterol. 2015;110(8):1205–15. DOI: 10.1038/ajg.2015.158
31. Liebregts T., Adam B., Bredack C., Gururatsakul M., Pilkington K.R., Brierley S.M., et al. Small bowel hom ing T cells are associated with symptoms and delayed gastric emptying in functional dyspepsia. Am J Gastroenterol. 2011;106(6):1089–98. DOI: 10.1038/ajg.2010.512
32. Ivashkin V.T., Maev I.V., Trukhmanov A.S., Sheptulin A.A., Lapi na T.L., Simanenkov V.I., et al. Inflammation, impaired motor function and visceral hypersensitivity: The main mechanisms of functional disorders of the gastrointestinal tract (materials of the Expert Council and literature review). Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(1):7–14. (In Russ.). DOI: 10.22416/1382-4376-2022-32-1-7-14
33. Dunbar K.B., Agoston A.T., Odze R.D., Huo X., Pham T.H., Cipher D.J., et al. Association of acute gastroesophageal reflux disease with esophageal histologic changes. JAMA. 2016;315(19):2104–12. DOI: 10.1001/jama.2016.5657
34. Kohata Y., Nakahara K., Tanigawa T., Yamagami H., Shiba M., Watanabe T., et al. Rebamipide alters the esophageal microbiome and reduces the incidence of Barrett’s esophagus in a rat model. Dig Dis Sci. 2015;60(9):2654–61. DOI: 10.1007/s10620-015-3662-4
35. Zhong Y.Q., Lin Y., Xu Z. Expression of IFN-γ and IL-4 in the esophageal mucosa of patients with reflux esophagitis and Barrett’s esophagus and their relationship with endoscopic and histologic grading. Dig Dis Sci. 2011;56(10):2865–70. DOI: 10.1007/s10620-011-1696-9
36. Rieder F., Biancani P., Harnett K., Yerian L., Falk G.W. Inflammatory mediators in gastroesophageal reflux disease: Impact on esophageal motility, fibrosis, and carcinogenesis. Am J Physiol Gastrointest Liver Physiol. 2010;298(5):G571–81. DOI: 10.1152/ajpgi.00454.2009
37. Paraskevova A.V., Trukhmanov A.S., Storonova O.A., Lyamina S.V., Kalish S.V., Piro gov S.S., et al. Macrophage phenotype after human refluxate exposure, esophageal dysmotility and their correlation with gastroesophageal reflux disease. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(1):24–33. (In Russ.). DOI: 10.22416/1382-43762022-32-1-24-33
38. Ronkainen J., Aro P., Walker M.M., Agréus L., Jo hansson S.E., Jones M., et al. Duodenal eosinophilia is associated with functional dyspepsia and new onset gastro-oesophageal reflux disease. Aliment Pharmacol Ther. 2019;50(1):24–32. DOI: 10.1111/apt.15308
39. Talley N.J., Walker M.M., Aro P., Ronkainen J., Storskrubb T., Hindley L.A., et al. Non-ulcer dyspepsia and duodenal eosinophilia: An adult endoscopic population-based case-control study. Clin Gastroenterol Hepatol. 2007;5(10):1175–83. DOI: 10.1016/j.cgh.2007.05.015
40. Walker M.M., Aggarwal K.R., Shim L.S., Bassan M., Kalantar J.S., Weltman M.D., et al. Duodenal eosinophilia and early satiety in functional dyspepsia: Confirmation of a positive association in an Australian cohort. J Gastroenterol Hepatol. 2014;29(3):474–9. DOI: 10.1111/jgh.12419
41. Vanheel H., Vicario M., Vanuytsel T., Van Oudenhove L., Martinez C., Keita Å.V., et al. Impaired duodenal mucosal integrity and low-grade inflammation in functional dyspepsia. Gut. 2014;63(2):262–71. DOI: 10.1136/gutjnl-2012-303857
42. Jones M.P., Walker M.M., Ford A.C., Talley N.J. The overlap of atopy and functional gastrointestinal disorders among 23,471 patients in primary care. Aliment Pharmacol Ther. 2014;40(4):382–91. DOI: 10.1111/apt.12846
43. Walker M.M., Salehian S.S., Murray C.E., Rajen dran A., Hoare J.M., Negus R., et al. Implications of eosinophilia in the normal duodenal biopsy — an association with allergy and functional dyspepsia. Aliment Pharmacol Ther. 2010;31(11):1229–36. DOI: 10.1111/j.13652036.2010.04282.x
44. Futagami S., Shindo T., Kawagoe T., Horie A., Shimpuku M., Gudis K., et al. Migration of eosinophils and CCR2-/CD68-double positive cells into the duodenal mucosa of patients with postinfectious functional dyspepsia. Am J Gastroenterol. 2010;105(8):1835–42. DOI: 10.1038/ajg.2010.151
45. Friesen C.A., Sandridge L., Andre L., Roberts C.C., Abdel-Rahman S.M. Mucosal eosinophilia and response to H1/H2 antagonist and cromolyn therapy in pediatric dyspepsia. Clin Pediatr (Phila). 2006;45(2):143–7. DOI: 10.1177/000992280604500205
46. Friesen C.A., Andre L., Garola R., Hodge C., Rob erts C. Activated duodenal mucosal eosinophils in children with dyspepsia: A pilot transmission electron microscopic study. J Pediatr Gastroenterol Nutr. 2002;35(3):329–33. DOI: 10.1097/00005176-200209000-00017
47. Harer K.N., Hasler W.L. Functional dyspepsia: A review of the symptoms, evaluation, and treatment options. Gastroenterol Hepatol (N Y). 2020;16(2):66–74.
48. Kaybysheva V.O., Storonova O.A., Trukhmanov A.S., Ivashkin V.T. Intraesophageal pH-impedance measurement in diagnosis of GERD. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2013;2:4–12. (In Russ.).
49. Lee K.J., Demarchi B., Demedts I., Sifrim D., Raeymaekers P., Tack J. A pilot study on duodenal acid exposure and its relationship to symptoms in functional dyspepsia with prominent nausea. Am J Gastroenterol. 2004;99(9):1765–73. DOI: 10.1111/j.15720241.2004.30822.x
50. Bratten J., Jones M.P. Prolonged recording of duodenal acid exposure in patients with functional dyspepsia and controls using a radiotelemetry pH monitoring system. J Clin Gastroenterol. 2009;43(6):527–33. DOI: 10.1097/MCG.0b013e31818e37ab
51. Lee K.J., Kim J.H., Cho S.W. Dyspeptic symptoms associated with hypersensitivity to gastric distension induced by duodenal acidification. J Gastroenterol Hepatol. 2006;21(3):515–20. DOI: 10.1111/j.1440-1746.2005.03976.x
52. Miwa H., Nagahara A., Asakawa A., Arai M., Oshima T., Kasugai K., et al. Evidence-based clinical practice guidelines for functional dyspepsia 2021. J Gastroenterol. 2022;57(2):47–61. DOI: 10.1007/s00535-021-01843-7
53. Lee K.J., Vos R., Janssens J., Tack J. Influence of duodenal acidification on the sensorimotor function of the proximal stomach in humans. Am J Physiol Gastrointest Liver Physiol. 2004;286(2):G278–84. DOI: 10.1152/ajpgi.00086.2003
54. Xiao Y.L., Peng S., Tao J., Wang A.J., Lin J.K., Hu P.J., et al. Prevalence and symptom pattern of pathologic esophageal acid reflux in patients with functional dyspepsia based on the Rome III criteria. Am J Gastroenterol. 2010;105(12):2626–31. DOI: 10.1038/ajg.2010.351
55. Tack J., Caenepeel P., Arts J., Lee K.J., Sifrim D., Janssens J. Prevalence of acid reflux in functional dyspepsia and its association with symptom profile. Gut. 2005;54(10):1370–6. DOI: 10.1136/gut.2004.053355
56. Sheptulin A.A., Rabotyagova Yu.S. Modern possibil ities of using acotiamide in the treatment of functional dyspepsia. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(1):70–5. (In Russ.). DOI: 10.22416/1382-43762024-34-1-70-75
57. Pinto-Sanchez M.I., Yuan Y., Hassan A., Bercik P., Moayyedi P. Proton pump inhibitors for functional dyspepsia. Cochrane Database Syst Rev. 2017;11(11):CD011194. DOI: 10.1002/14651858.CD011194.pub3
58. Pittayanon R., Yuan Y., Bollegala N.P., Khanna R., Lacy B.E., Andrews C.N., et al. Prokinetics for functional dyspepsia: A systematic review and meta-analysis of randomized control trials. Am J Gastroenterol. 2019;114(2):233–43. DOI: 10.1038/s41395-018-0258-6
59. Moayyedi P., Delaney B.C., Vakil N., Forman D., Talley N.J. The efficacy of proton pump inhibitors in nonulcer dyspepsia: A systematic review and economic analysis. Gastroenterology. 2004;127(5):1329–37. DOI: 10.1053/j.gastro.2004.08.026
60. Evsyutina Yu.V. How to make the right choice of proton pump inhibitor for patients with gastroesophageal reflux disease? Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2023;33(1):68–76. (In Russ.). DOI: 10.22416/1382-4376-2023-33-1-68-76
61. Moayyedi P., Soo S., Deeks J., Delaney B., Innes M., Forman D. Pharmacological interventions for non-ulcer dyspepsia. Cochrane Database Syst Rev. 2006;4:CD001960. DOI: 10.1002/14651858.CD001960.pub3
62. Xi L., Zhu J., Zhang H., Muktiali M., Li Y., Wu A. The treatment efficacy of adding prokinetics to PPIs for gastroesophageal reflux disease: A meta-analysis. Esophagus. 2021;18(1):144–51. DOI: 10.1007/s10388-020-00753-6
63. Malfertheiner P., Megraud F., Rokkas T., Gisbert J.P., Liou J.M., Schulz C., et al.; European Helicobacter and Microbiota Study group. Management of Helicobacter pylori infection: The Maastricht VI/Florence consensus report. Gut. 2022:gutjnl-2022-327745. DOI: 10.1136/gutjnl-2022-327745
64. Ivashkin V.T., Lapina T.L., Maev I.V., Drapkina O.M., Kozlov R.S., Sheptulin A.A., et al. Clinical practice guidelines of Russian Gastroenterological Association, Scientific Society for the Clinical Study of Human Microbiome, Russian Society for the Prevention of Non-Communicable Diseases, Interregional Association for Clinical Microbiology and Antimicrobial Chemotherapy for Н. pylori diagnostics and treatment in adults. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2022;32(6):72–93. (In Russ.). DOI: 10.22416/1382-4376-2022-32-6-72-93
65. Ivashkin V.T., Maev I.V., Lapina T.L., Fedorov E.D., Sheptulin A.A., Trukhmanov A.S., et al. Clinical recommendations of Russian Gastroenterological Association and RENDO Endoscopic Society on diagnosis and treatment of gastritis and duodenitis. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2021;31(4):70–99. (In Russ.). DOI: 10.22416/1382-4376-2021-31-4-70-99
66. Evaluation and Licensing Division, Pharmaceutical and Food Safety Bureau, Ministry of Health, Labour and Welfare. Report on the deliberation results (Aco fide tablets 100 mg). URL: https://www.pmda.go.jp/files/000153467.pdf
67. Yamawaki H., Futagami S., Kawagoe T., Maruki Y., Hashimoto S., Nagoya H., et al. Improvement of meal-related symptoms and epigastric pain in patients with functional dyspepsia treated with acotiamide was associated with acylated ghrelin levels in Japan. Neurogastroenterol Motil. 2016;28(7):1037–47. DOI: 10.1111/nmo.12805
68. Yagi T., Asakawa A., Ueda H., Miyawaki S., Inui A. The role of ghrelin in patients with functional dyspepsia and its potential clinical relevance (Review). Int J Mol Med. 2013;32(3):523–31. DOI: 10.3892/ijmm.2013.1418
69. Shindo T., Futagami S., Hiratsuka T., Horie A., Hamamoto T., Ueki N., et al. Comparison of gastric emptying and plasma ghrelin levels in patients with functional dyspepsia and non-erosive reflux disease. Digestion. 2009;79(2):65–72. DOI: 10.1159/000205740
70. Xiao G., Xie X., Fan J., Deng J., Tan S., Zhu Y., et al. Efficacy and safety of acotiamide for the treatment of functional dyspepsia: Systematic review and meta-analysis. ScientificWorldJournal. 2014;2014:541950. DOI: 10.1155/2014/541950
71. Matsueda K., Hongo M., Tack J., Aoki H., Saito Y., Kato H. Clinical trial: Dose-dependent therapeutic efficacy of acotiamide hydrochloride (Z-338) in patients with functional dyspepsia — 100 mg t.i.d. is an optimal dosage. Neurogastroenterol Motil. 2010;22(6):618–e173. DOI: 10.1111/j.1365-2982.2009.01449.x
72. Matsueda K., Hongo M., Ushijima S., Akiho H. A longterm study of acotiamide in patients with functional dyspepsia: Results from an open-label phase III trial in Japan on efficacy, safety and pattern of administration. Digestion. 2011;84(4):261–8. DOI: 10.1159/000332404
73. Matsueda K., Hongo M., Tack J., Saito Y., Kato H. A placebo-controlled trial of acotiamide for meal-related symptoms of functional dyspepsia. Gut. 2012;61(6):821–8. DOI: 10.1136/gutjnl-2011-301454
74. Kusunoki H., Haruma K., Manabe N., Imamura H., Kamada T., Shiotani A., et al. Therapeutic efficacy of acotiamide in patients with functional dyspepsia based on enhanced postprandial gastric accommodation and emptying: Randomized controlled study evaluation by real-time ultrasonography. Neurogastroenterol Motil. 2012;24(6):540–5, e250–1. DOI: 10.1111/j.1365-2982.2012.01897.x
75. Shinozaki S., Osawa H., Sakamoto H., Hayashi Y., Kawarai Lefor A., Yamamoto H. The effect of acotiamide on epigastric pain syndrome and postprandial distress syndrome in patients with functional dyspepsia. J Med Invest. 2016;63(3–4):230–5. DOI: 10.2152/jmi.63.230
76. Shinozaki S., Osawa H., Sakamoto H., Hayashi Y., Mi ura Y., Lefor A.K., et al. Adherence to an acotiamide therapeutic regimen improves long-term outcomes in patients with functional dyspepsia. J Gastrointestin Liver Dis. 2017;26(4):345–50. DOI: 10.15403/jgld.2014.1121.264.ski
77. Tack J., Pokrotnieks J., Urbonas G., Banciu C., Yakusevich V., Bunganic I., et al. Long-term safety and efficacy of acotiamide in functional dyspepsia (postprandial distress syndrome) — results from the European phase 3 open-label safety trial. Neurogastroenterol Motil. 2018;30(6):e13284. DOI: 10.1111/nmo.13284
78. Muta K., Ihara E., Fukaura K., Tsuchida O., Ochi ai T., Nakamura K. Effects of acotiamide on the esophageal motility function in patients with esophageal motility disorders: A pilot study. Digestion. 2016;94(1):9–16. DOI: 10.1159/000447010
79. Mizukami K., Katsuta M., Okamoto K., Fukuda K., Ogawa R., Kawahara Y., et al. Influence of acotiamide on 13C-urea breath test for Helicobacter pylori diagnosis. J Clin Biochem Nutr. 2020;67(3):332–7. DOI: 10.3164/jcbn.20-17
80. Bakulin I.G., Khlynov I.B., Sablin O.A., Pakhomova I.G., Pavlova N.V. Clinical efficacy of acotiamide in patients with functional dyspepsia: Results of a multicenter study. Medical Council. 2023;(13):108–15. (In Russ.). DOI: 10.21518/ms2023-253
81. Mayanagi S., Kishino M., Kitagawa Y., Sunamura M. Efficacy of acotiamide in combination with esomeprazole for functional dyspepsia refractory to proton-pump inhibitor monotherapy. Tohoku J Exp Med. 2014;234(3):237– 40. DOI: 10.1620/tjem.234.237
82. Black C.J., Paine P.A., Agrawal A., Aziz I., Eugeni cos M.P., Houghton L.A., et al. British Society of Gastroenterology guidelines on the management of functional dyspepsia. Gut. 2022;71(9):1697–723. DOI: 10.1136/gutjnl-2022-327737
83. Yamashita H., Okada A., Naora K., Hongoh M., Kinoshita Y. Adding acotiamide to gastric acid inhibitors is effective for treating refractory symptoms in patients with non-erosive reflux disease. Dig Dis Sci. 2019;64(3):823–31. DOI: 10.1007/s10620-018-5377-9
84. Funaki Y., Ogasavara N., Kawamura Y., Yoshimine T., Tamura Y., Izawa S., et al. Effects of acotiamide on functional dyspepsia patients with heartburn who failed proton pump inhibitor treatment in Japanese patients: A randomized, double-blind, placebo-controlled crossover study. Neurogastroenterol Motil. 2020;32(2):e13749. DOI: 10.1111/nmo.13749
85. Takeuchi T., Takahashi Y., Kawaguchi S., Ota K., Harada S., Kojima Y., et al. Therapy of gastroesophageal reflux disease and functional dyspepsia overlaps with symptoms after usual-dose proton pump inhibitor: Acotiamide plus usual-dose proton pump inhibitor versus double-dose proton pump inhibitor. J Gastroenterol Hepatol. 2018;33(3):623–30. DOI: 10.1111/jgh.13970
Review
For citations:
Trukhmanov A.S., Rumyantseva D.E. Functional Dyspepsia and Gastroesophageal Reflux Disease: From Pathogenesis to Current Treatment Strategies. Russian Journal of Gastroenterology, Hepatology, Coloproctology. 2024;34(5):83-92. https://doi.org/10.22416/1382-4376-2024-34-5-83-92
Views:
777
Email this article 
